U.S. stock futures were in the red Tuesday, but trembled deeper Greece-fueled losses ahead the latest housing-market index, the Empire state manufacturing reading and a Federal Reserve speaker, all due later in the day.
On Friday, Health care stocks were mostly higher.
The S&P 500 has moved out more than three years without a ricochet back of 10 percent or more, known as a correction. Still, a strong dollar and a sink in oil prices that threaten investment and earnings growth have tested the flexibility of investors as the bull market nears its seventh year.
Earnings for S&P 500 companies climbed 4.2 percent last quarter, and will almost certainly drop in the next two periods, according to analysts’ forecasts collected by Bloomberg. More than three-quarters of the S&P 500 companies have confirmed results for the final three months of 2014, with 76 percent beating profit estimates, data compiled by Bloomberg show.
Wal-Mart Stores Inc., Noble Energy Inc., and Discovery Communications Inc. are among companies releasing financial results this week.
Among stocks that moved on corporate news, Halliburton Co. gained 1.8 percent in premarket New York trading as a person with knowledge of the matter said ValueAct Capital Administration LP has attaind a new stake in the company of about 3.5 percent.
SunEdison Inc. added 1.5 percent in late New York trading Friday after David Einhorn’s Greenlight Capital and Daniel Loeb’s Third Point LLC stated raised stakes in the solar company.
U.S. stock markets are shut on Monday for the Presidents’ Day occasion.
Below is described the comprehensive details of few biotech sector stocks that lands in the bullish zone Friday, following the trend of U.S. Market:
Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) gained 9.57%, and closed at $7.67, during the last trading session, and was a big mover last session, as the company saw its shares rise nearly 19% on the day. The share price rallied on the company’s participation in the Leerink Global Healthcare Conference in New York City and the bullish sentiment of investors on the outcome of the meet. This led to more shares changing hands than in a normal session. Yesterday’s rally continues the uptrend for the company since Feb 4, as the stock is now up almost 45%.
Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) is global biosimilar company focused on improving patient access to important medicines. EPIRUS’ operationally synergistic pipeline of biosimilar product candidates comprises BOW015 (infliximab), BOW050 (adalimumab) and BOW070 (tocilizumab).
Synthetic Biologics Inc (NYSEMKT:SYN) enhanced 9.23%, and closed at $2.13, during the last trading session, after a biotechnology company, declared positive top line safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company’s investigational oral beta-lactamase enzyme designed to protect the micro biome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
Synthetic Biologics Inc (NYSEMKT:SYN) is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome.
Exelixis, Inc (NASDAQ:EXEL) raised 8.77%, and closed at $2.48, during the last trading session, after a biopharmaceutical company, declared that its fourth quarter and full year 2014 financial results will be released on Tuesday, February 24, 2015 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis administration will host a conference call to talk about the results and provide a general business update. The conference call will be accessible via the Internet from the Company’s website.
Exelixis, Inc (NASDAQ:EXEL) is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases.
CytRx Corporation (NASDAQ:CYTR) raised 8.42%, and closed at $2.96, during the last trading session, as a biopharmaceutical research and development company, formerly on January 22, 2015 declared encouraging overall survival (OS) results, the secondary endpoint, from its accomplished multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin contrast with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). The OS results in 123 patients demonstrated that aldoxorubicin-treated patients demonstrated a 27 percent reduction in the risk of death contrast to patients treated with doxorubicin (HR 0.73: 95% confidence interval 0.44-1.20), the current standard-of-care in this indication.
CytRx Corporation (NASDAQ:CYTR), operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate comprises aldoxorubicin that has accomplished Phase IIb clinical trial as a first-line therapy for soft tissue sarcomas; and has initiated an international Phase II clinical trial in patients with late-stage glioblastoma multiforme, and a Phase II clinical trial in HIV-related Kaposi’s sarcoma.
